NVCT vs. XERS, MGTX, QURE, IMTX, ORIC, MNMD, ANAB, PGEN, KALV, and CGEM
Should you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Xeris Biopharma (XERS), MeiraGTx (MGTX), uniQure (QURE), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Mind Medicine (MindMed) (MNMD), AnaptysBio (ANAB), Precigen (PGEN), KalVista Pharmaceuticals (KALV), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.
Nuvectis Pharma vs.
Xeris Biopharma (NASDAQ:XERS) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.
Xeris Biopharma presently has a consensus price target of $5.15, indicating a potential upside of 39.57%. Nuvectis Pharma has a consensus price target of $11.00, indicating a potential upside of 79.15%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Nuvectis Pharma is more favorable than Xeris Biopharma.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 35.8% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Xeris Biopharma has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.
Nuvectis Pharma has lower revenue, but higher earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma received 134 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 90.91% of users gave Nuvectis Pharma an outperform vote while only 69.90% of users gave Xeris Biopharma an outperform vote.
Nuvectis Pharma has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Nuvectis Pharma's return on equity.
In the previous week, Nuvectis Pharma had 18 more articles in the media than Xeris Biopharma. MarketBeat recorded 22 mentions for Nuvectis Pharma and 4 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.41 beat Nuvectis Pharma's score of 0.03 indicating that Xeris Biopharma is being referred to more favorably in the media.
Summary
Nuvectis Pharma beats Xeris Biopharma on 9 of the 17 factors compared between the two stocks.
Get Nuvectis Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvectis Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:NVCT) was last updated on 3/4/2025 by MarketBeat.com Staff
Free NVCT Stock Alerts